AstraZeneca PLC (AZN.L) — Quality & forensics
As of 2026-11-10 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 44
- Quality 75
- Growth 51
- Balance sheet 47
- Cash quality 45
- Capital allocation 52
- Momentum 60
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the AZN.L chart & overview
FAQ · from the current data · as of 2026-11-10
Quick answers
What is AstraZeneca PLC's Closelooknet quality reading?
The composite reads 55/100 across 7 modules, as of 2026-11-10: valuation 44, quality 75, growth 51, balance sheet 47, cash quality 45, capital allocation 52, momentum 60. Closelooknet scores are research diary readings, not ratings or investment advice.
What is AstraZeneca PLC's Altman Z-Score?
3.03, which sits in the safe zone (above 2.99) as of 2026-11-10. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is AstraZeneca PLC's Piotroski F-Score?
9 of 9, as of 2026-11-10. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does AstraZeneca PLC's Beneish M-Score indicate?
-2.45 — below the −1.78 manipulation-risk threshold, as of 2026-11-10. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- LLY Eli Lilly and Companyindustry
- ORNAV.HE Orion Oyj Aindustry
- ORNBV.HE Orion Oyj Bindustry
- SAN.PA Sanofi SAindustry
- GSK GSK plcindustry
- NVO Novo Nordisk A/Sindustry
- SNY Sanofi ADRindustry
- GILD Gilead Sciences Incindustry
- BIIB Biogen Incindustry
- ABBV AbbVie Incindustry
- 002422.SHE Sichuan Kelun Pharmaceutical Co Ltdindustry
- JNJ Johnson & Johnsonindustry
- PFE Pfizer Incindustry
- BMY Bristol-Myers Squibb Companyindustry
- MRK Merck & Company Incindustry
- OGN Organon & Coindustry
- AZN AstraZeneca PLCindustry
- CMHC.SW COSMO N NVindustry
- CTEC.L ConvaTec Group PLCsector
- HCM.L HUTCHMED China Ltdsector